At Spinogenix, we are developing first-in-class therapeutics to restore synapses – the critical connections between neurons that allow us to think, plan, remember, and control motor functions. Understanding and restoring these synaptic connections could revolutionize treatments for a variety of neurodegenerative, neurodevelopmental, and neuropsychiatric conditions.

The nervous system, comprising the brain, spinal cord, and nerves, is responsible for your senses, movement, basic bodily functions, learning, and memory. When this system breaks down, as it does in neurodegenerative conditions, the communication signals across synapses fail. This breakdown leads to the loss of cognitive and motor functions, profoundly impacting millions of lives.

Spinogenix is currently in Phase 2 clinical trials exploring our therapeutics for the treatment of ALS, Alzheimer’s disease, and Fragile X syndrome. Our therapies are a simple once-a-day pill for ease of treatment administration, aiming to restore synaptic function and make a meaningful impact for patients.

It is at your physician’s discretion to evaluate enrollment criteria and eligibility for clinical trial participation.